Tags : Halozyme

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Tuba Khan November 4, 2019

Shots: Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients […]readmore

Biotech

Argenx Signs a Worldwide License Agreement with Halozyme for its

Vartika Singh February 5, 2019

Shots: Halozyme to receive $30M upfront, $160M milestones, $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting […]readmore

Tags : Halozyme

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Argenx Signs a Worldwide License Agreement with Halozyme for its

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Halozyme

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Argenx Signs a Worldwide License Agreement with Halozyme for its

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company